Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Androgen receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    81 result(s) found for: Androgen receptor. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2010-021790-37 Sponsor Protocol Number: UK_S-H_08_0006 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Lübeck
    Full Title: Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)
    Medical condition: The medical condition under investigation is complete androgen insensitivity syndrome (CAIS) in gonadectomized patients with 46,XY karyotype due to mutations of the androgen receptor, which lead to...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10056292 Androgen insensitivity syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002210-36 Sponsor Protocol Number: PR2006-03 Start Date*: 2006-11-10
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase II study evaluating intravenous Melphalan with autologous whole blood stem cell transplantation (PBSCT) in patients with Androgen –Independent Prostate Cancer (AIPC)
    Medical condition: Open-labelled, non-randomised, treatment intensifying cohort study in androgen-independent prostate cancer (AIPC.)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001398-44 Sponsor Protocol Number: PR 2006-04 Start Date*: 2006-06-13
    Sponsor Name:Barts and The London NHS Trust
    Full Title: The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer
    Medical condition: The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer. Open-labeled, non-randomised clinical trial in patients with androgen indep...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001634-17 Sponsor Protocol Number: 2015.0704 Start Date*: 2015-12-24
    Sponsor Name:University Medical Center Groningen
    Full Title: 18FDHT-PET to visualize the effect on the androgen receptor level by bicalutamide
    Medical condition: androgen receptor positive metastatic breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000476-26 Sponsor Protocol Number: N14DAR Start Date*: 2020-07-13
    Sponsor Name:Netherlands Cancer Institute
    Full Title: Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA)
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036912 Prostate cancer stage 0 PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036917 Prostate cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036919 Prostate cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036918 Prostate cancer stage II PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003761-17 Sponsor Protocol Number: RADAR-1CRPC Start Date*: 2020-04-02
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: A RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone or enzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic ...
    Medical condition: Castration resistant prostate cancer docetaxel and androgen receptor-targeted agent (abiraterone or enzalutamide) naïve.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003981-42 Sponsor Protocol Number: 2012.2708 Start Date*: 2014-10-20
    Sponsor Name:University Medical Center Groningen [...]
    1. University Medical Center Groningen
    2. VUMC
    Full Title: Estrogen receptor and androgen receptor imaging in metastatic breast cancer patients
    Medical condition: Estrogen receptor positive metastatic breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001933-16 Sponsor Protocol Number: 26866138PCR2002 Start Date*: 2007-03-13
    Sponsor Name:Christos N. Papandreou
    Full Title: "A Phase II, Open-Label study of Velcade(Bortezomib)for patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy"
    Medical condition: Treatment of patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy.
    Disease:
    Population Age: Gender: Male
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004756-20 Sponsor Protocol Number: EFC6546 Start Date*: 2007-09-19
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastat...
    Medical condition: Patients with metastatic androgen-independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) SE (Completed) CZ (Completed) PT (Completed) ES (Completed) DK (Completed) HU (Completed) EE (Completed) BE (Completed) NL (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000314-38 Sponsor Protocol Number: 1206-HNCG Start Date*: 2014-07-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expre...
    Medical condition: Salivary gland cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) HU (Completed) AT (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000543-13 Sponsor Protocol Number: UoL001204 Start Date*: 2016-12-28
    Sponsor Name:University of Liverpool
    Full Title: A window of opportunity study to assess the biological effects of enobosarm in oestrogen receptor positive, androgen receptor positive early breast cancer
    Medical condition: oestrogen receptor, androgen receptor positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002284-18 Sponsor Protocol Number: UC-0140/1711 Start Date*: 2017-12-02
    Sponsor Name:UNICANCER
    Full Title: A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally advanced (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine
    Medical condition: Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally advanced (unresectable) or metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004485-21 Sponsor Protocol Number: HE9A/14 Start Date*: 2015-04-03
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment
    Medical condition: Castration resistant bone metastatic prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000994-30 Sponsor Protocol Number: VD1.3 Start Date*: 2013-02-19
    Sponsor Name:Medizinische Universität Graz
    Full Title: A randomized, double‐blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on metabolic and fertility parameters in PCOS women
    Medical condition: Polycystic Ovary Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002071-29 Sponsor Protocol Number: ITT012“ELISA” Start Date*: 2014-12-22
    Sponsor Name:DIPARTIMENTO DI ONCOLOGIA MEDICA USL8
    Full Title: A RANDOMIZED PROSPECTIVE MULTICENTRE PHASE II STUDY OF ANDROGEN DEPRIVATION THERAPY (ADT) PLUS RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN LOCALLY ADVANCED VERY HIGH-RISK PRO...
    Medical condition: LOCALLY ADVANCED VERY HIGH-RISK PROSTATE CANCER
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10029002 Neoplasm of the prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003865-32 Sponsor Protocol Number: TOK-200-11 Start Date*: 2014-02-12
    Sponsor Name:Tokai Pharmaceuticals, Inc.
    Full Title: A Pharmacokinetic and Pharmacodynamic Translational Investigation of Galeterone in Patients with Metastatic Castration Resistant Prostate Cancer
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10066489 Progression of prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001162-10 Sponsor Protocol Number: EUOG2014-002 Start Date*: 2015-05-06
    Sponsor Name:European Uro- Oncology Group (EUOG)
    Full Title: An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Hormono-Naïve patients with Metastatic Prostate ...
    Medical condition: Patients with Metastatic Prostate Cancer who have never been treated with Androgen Deprivation Therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005079-10 Sponsor Protocol Number: TOK-200-15 Start Date*: 2015-07-14
    Sponsor Name:Tokai Pharmaceuticals Inc
    Full Title: ARMOR3-SV: A Phase 3, Randomized, Open-Label, Multi-Center, Controlled Study of Galeterone Compared with Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA with Metastatic Cast...
    Medical condition: Androgen receptor (AR) splice variant-7 (ARV7), metastatic (M1) castration resistant prostate cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10007453 Carcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002587-28 Sponsor Protocol Number: BGB-290-202 Start Date*: 2019-08-30
    Sponsor Name:BeiGene, Ltd.
    Full Title: A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD)
    Medical condition: Patients with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-000722-54 Sponsor Protocol Number: MDV3100-10(C3431013) Start Date*: 2013-10-17
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Can...
    Medical condition: Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FI (Completed) DE (Ongoing) SK (Completed) BE (Completed) SE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:02:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA